Mechanism of Action:
Binds to GLP-1 receptors in pancreas
Stimulates glucose-dependent insulin secretion
Suppresses glucagon secretion
Slows gastric emptying
Reduces appetite and food intake
Recommended for:
Patients with type 2 diabetes
Individuals with obesity (BMI ≥ 30)
Patients with overweight (BMI ≥ 27) with comorbidities
When oral antidiabetic drugs are ineffective
For cardiovascular risk reduction in diabetic patients
Research and Studies:
Clinical studies demonstrate:
1.0-1.5% reduction in HbA1c levels
5-8% weight loss over 6 months
Reduction in major adverse cardiovascular events risk
Improvement in postprandial glycemic control
2-5 mmHg reduction in systolic blood pressure
Type 2 diabetes mellitus
Obesity (BMI ≥ 30 kg/m²)
Overweight (BMI ≥ 27 kg/m²) with comorbidities
Prevention of cardiovascular events in diabetic patients
The drug is dissolved in appropriate volume of solvent and administered subcutaneously once weekly. Starting dose is 0.25 mg once weekly for 4 weeks, then dose is increased to 0.5 mg once weekly. Maintenance dose is 1 mg once weekly.
Contraindications:
Type 1 diabetes mellitus
Diabetic ketoacidosis
Severe gastrointestinal diseases
Severe renal failure
Pregnancy and lactation
Side Effects:
Nausea
Vomiting
Diarrhea
Constipation
Decreased appetite
